New catheter-less technique may ease the pain and discomfort of prostate cancer recovery

To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter. The new patentable technique, used in conjunction with robotic prostatectomy -- the surgical removal of the prostate -- eliminates the pain and discomfort associated with the standard catheter.

"Robotic surgery offers better cosmetic benefits, reduced pain, early continence, a high rate of sexual potency, and minimal blood loss, all without sacrificing the success of cancer elimination," explains lead researcher Dr. Ashutosh K. Tewari, director of robotic prostatectomy and outcomes research at NewYork-Presbyterian/Weill Cornell and the Ronald P. Lynch Associate Professor of Urologic Oncology at Weill Cornell Medical College.

"But, now, the new technique we are studying may further enhance the comfort for our patients," says Dr. Tewari.

The new study is published today in the British Journal of Urology International.

The research team studied 50 patients -- 30 implanted with the custom designed device, and 20 who received the standard penile catheter. The two groups were comparable in age, prostate specific antigen (PSA) level, body mass index (BMI), the grade and stage of the cancer, length of surgery, blood loss, and several other operative measures. The results were positive.

The control group experienced penile pain and discomfort nine times greater than the experimental group, and seven times greater discomfort while walking and sleeping. There were no serious side effects observed in either group.

"The results are very exciting because through this new technology, we are able to continually improve on the robotic surgical option that has already given men a high rate of continence and sexual function," says Dr. Tewari.

Because robotic surgery has vastly improved recovery -- allowing patients to return home within one day of the procedure -- patients will often focus on the penile and urinary discomfort caused by the catheter's implantation and following removal. The new approach, developed by Dr. Tewari and his team, avoids implantation of an irritating catheter through the penis' urethra -- the tube connected to the urinary bladder that allows for the passage of urine and seminal fluid to the outside of the body.

The new approach re-routes urine directly from the bladder by way of a narrow tube that exits through a small needle puncture below the gut, and also serves to support the internal urinary structures as the patient heals.

Past studies examining the advantages of avoiding catheter use have indicated that they impart less risk for bacterial infection, reduce discomfort, and reduce the need for re-catheterization.

"In the future, the new technique might also be used effectively for non-robotic prostate removal," says Dr. Tewari.

However, Dr. Tewari says that not all patients may be a candidates for this new option based on their body mass and amount of abdominal fat, prostate size, or those who are taking blood thinning drugs or who have a higher likelihood of bleeding.

These new findings build upon the groundbreaking work of Dr. Tewari, and his collaborators in the Department of Urology at NewYork-Presbyterian/Weill Cornell, to better improve the lifestyles of patients following prostate removal, such as the reconstruction and sparing of nerves and muscles in order to preserve urinary continence and sexual function. Dr. Tewari is a leader in the field of robotic prostate surgery and has been involved with over 2,500 surgeries to date.

Source: New York- Presbyterian Hospital

Related stories:

Prostate cancer gene test provides new early detection
Prostate cancer (PCa) is one of the most common male cancers in the Western world. Currently, early detection of PCa depends on an abnormal digital rectal examination and an elevated prostate-specific-antigen (PSA) level requiring a prostate biopsy, often associated with anxiety, discomfort, complications, and heavy expenses. The prostate-cancer-gene-3 (PCA3) test is a new PCa gene-based marker carried out with a urine sample. PCA3 is highly specific to PCa and has shown promising early detection results at repeat biopsy. It may allow patients to avoid unnecessary biopsies. The PCA3 gene is dominant in over 95% of malignant prostate tissue compared to benign and normal prostate tissue.
Biomarker predicts malignancy potential of HG-PIN lesions in the prostate
Men whose prostate cancer screenings show high grade prostatic intraepithelial neoplasia (HG-PIN) may find themselves in limbo, “stuck” between diagnoses – they are told prostate cancer has not yet developed, but it might, and they are advised to undergo repeated needle biopsies as a precaution.
Cellular senescence a double-edged sword
Scientists have identified a molecular cause behind the ravages of old age and in doing so have also shown how a natural process for fighting cancer in younger persons can actually promote cancer in older individuals. Cellular senescence, the process by which biological cells stop dividing in response to stress or damage to their DNA, was shown to trigger the secretion of proteins that cause inflammation in neighboring cells and tissue. Inflammation is linked to almost every major disease associated with aging, including many cancers.
Prostate cancer drug reduces testosterone levels in as little as 3 days
More than 95 per cent of men who took degarelix for prostate cancer saw their testosterone levels fall dramatically as early as three days after they started treatment, according to a paper in the December issue of BJU International.
Drop in cancer deaths tied primarily to gains in behavior and screening
Improvements in behavior and screening have contributed greatly to the 13 percent decline in cancer mortality since 1990, with better cancer treatments playing a supporting role, according to new research from David Cutler of Harvard University.
Prostate cancer spurs new nerves
Prostate cancer – and perhaps other cancers – promotes the growth of new nerves and the branching axons that carry their messages, a finding associated with more aggressive tumors, said researchers from Baylor College of Medicine in the first report of the phenomenon that appears today in the journal Clinical Cancer Research.
Nationwide study confirms PET as the most powerful imaging tool in cancer management
With the most recent release of data from the National Oncologic PET Registry (NOPR), researchers may have reached the moment of critical mass by confirming the effectiveness of positron emission tomography (PET) in the monitoring of tumor activity across a wide range of cancers.
Annual report finds declines in cancer incidence and death rates
A new report from the nation's leading cancer organizations shows that, for the first time since the report was first issued in 1998, both incidence and death rates for all cancers combined are decreasing for both men and women, driven largely by declines in some of the most common types of cancer. The report notes that, although the decreases in overall cancer incidence and death rates are encouraging, large state and regional differences in lung cancer trends among women underscore the need to strengthen many state tobacco control programs. The findings come from the "Annual Report to the Nation on the Status of Cancer, 1975-2005, Featuring Trends in Lung Cancer, Tobacco Use and Tobacco Control", online Nov. 25, 2008, and appearing in the Dec. 2, 2008, Journal of the National Cancer Institute.

News discussion:

Medicine & Health news